Jacobs & Co. CA lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 33.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,804 shares of the biopharmaceutical company's stock after selling 41,625 shares during the quarter. Jacobs & Co. CA's holdings in Pfizer were worth $1,993,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Valeo Financial Advisors LLC grew its stake in shares of Pfizer by 6.5% during the 2nd quarter. Valeo Financial Advisors LLC now owns 169,378 shares of the biopharmaceutical company's stock valued at $4,079,000 after buying an additional 10,375 shares during the period. Beaird Harris Wealth Management LLC grew its position in Pfizer by 42.7% during the second quarter. Beaird Harris Wealth Management LLC now owns 5,560 shares of the biopharmaceutical company's stock valued at $134,000 after acquiring an additional 1,663 shares during the period. Gradient Investments LLC increased its stake in Pfizer by 11.4% during the second quarter. Gradient Investments LLC now owns 13,131 shares of the biopharmaceutical company's stock worth $316,000 after acquiring an additional 1,346 shares during the last quarter. Rockland Trust Co. lifted its stake in shares of Pfizer by 1.0% in the 2nd quarter. Rockland Trust Co. now owns 430,196 shares of the biopharmaceutical company's stock valued at $10,359,000 after purchasing an additional 4,470 shares in the last quarter. Finally, Beacon Investment Advisory Services Inc. increased its position in Pfizer by 2.9% during the 2nd quarter. Beacon Investment Advisory Services Inc. now owns 25,404 shares of the biopharmaceutical company's stock worth $612,000 after purchasing an additional 716 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
PFE has been the subject of several research reports. JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Wednesday, July 8th. HSBC downgraded Pfizer from a "buy" rating to a "hold" rating and lowered their price target for the company from $32.00 to $28.00 in a report on Monday, July 6th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Finally, CICC Research initiated coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an "outperform" rating and a $33.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $28.28.
Check Out Our Latest Analysis on Pfizer
Pfizer Stock Performance
Shares of PFE opened at $26.70 on Friday. The stock has a market capitalization of $152.20 billion, a PE ratio of 35.14 and a beta of 0.34. The business's fifty day moving average price is $25.02 and its 200 day moving average price is $26.16. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.94. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the company earned $0.78 earnings per share. The firm's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.97 EPS for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer's payout ratio is presently 226.32%.
More Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Better-than-expected Q2 results supported the stock. Pfizer reported adjusted EPS of $0.77 versus the $0.68 consensus estimate and revenue of $15.03 billion versus expectations of $14.40 billion. The company also raised its 2026 revenue outlook, helping offset concerns about declining COVID-related sales. Pfizer Inc. Q2 2026 Earnings Call Summary
- Positive Sentiment: Pipeline progress is improving Pfizer’s longer-term outlook. Analysts highlighted the company’s broader pipeline, including the potential obesity treatment berobenatide and PF-07328948. Berobenatide is being compared with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, although Pfizer still faces significant development and competitive hurdles. Pfizer’s Next Weight-Loss Weapon
- Positive Sentiment: Pfizer and BioNTech advanced COVID-19 vaccine studies. A new Phase 4 study of a variant-adapted booster, along with progress on a next-generation pediatric booster, could support future vaccine demand and preserve the partnership’s commercial position. Variant-Adapted COVID-19 Booster Study
- Neutral Sentiment: Analyst opinion remains mixed. Some analysts are bullish after the earnings beat and pipeline updates, while RBC Capital maintained a Hold rating, indicating that valuation and execution risks continue to limit conviction. RBC Capital Remains a Hold on Pfizer
- Negative Sentiment: Patent expirations and obesity-program uncertainty remain overhangs. Investors are questioning whether Pfizer’s pipeline can replace revenue lost to upcoming patent cliffs, while previous obesity setbacks make the berobenatide opportunity particularly important but far from assured. Pfizer’s Patent and Pipeline Outlook
- Negative Sentiment: COVID product sales remain weak. Pfizer’s COVID pill revenue reportedly fell 95%, underscoring the company’s continuing dependence on non-COVID products and pipeline launches to drive growth. Pfizer COVID Pill Revenue Decline
Pfizer Profile
(
Free Report)
Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
